James F O'Mahony

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 17

Top Venues

PharmacoEconomics

PharmacoEconomics - open

HRB open research

Health economics, policy, and law

Trinity College Dublin

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Trinity College Dublin Aug 01 2018

Ireland

Assistant Research Professor :: Centre for Health Policy & Management

Trinity College Dublin Jan 01 2016 - Jul 31 2018

Ireland

Research Fellow :: Centre for Health Policy & Management

Trinity College Dublin Jan 01 2013 - Dec 31 2015

Ireland

Postdoctoral Research Fellow :: Centre for Health Policy & Management

Publications

Duco T Mülder, James F O'Mahony, Chyke A Doubeni, Iris Lansdorp-Vogelaar, Maartje H N Schermer
The Ethics of Cancer Screening Based on Race and Ethnicity. Annals of internal medicine (2024)
Yi-Shu Lin, James F O'Mahony, Joost van Rosmalen
A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R. PharmacoEconomics - open (2023)
Victoria Charlton, Michael J DiStefano, Polly Mitchell, Liz Morrell, Leah Zoe Gibson Rand, Gabriele Badano, Rachel Mairi Baker, Michael Calnan, Kalipso Chalkidou, Anthony J Culyer, Daniel Howdon, Dyfrig A Hughes, James Lomas, Catherine Max, Christopher McCabe, James F O'Mahony, Mike Paulden, Zack Pemberton-Whiteley, Annette Rid, Paul A Scuffham, Mark J Sculpher, Koonal Kirit Shah, Albert Weale, Gry Wester
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment. Health economics, policy, and law (2023)
Rajani Pokharel, Yi-Shu Lin, Ethna McFerran, James F O'Mahony
A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities? Applied health economics and health policy (2023)
Mariska M J Scheffer, Luc E Coffeng, James F O'Mahony
Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination: a systematic review. International journal of technology assessment in health care 39 (1) (2023)
Ethna McFerran, James F O'Mahony, Steffie Naber, Linda Sharp, Ann G Zauber, Iris Lansdorp-Vogelaar, Frank Kee
Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals? MDM policy & practice 7 (1) (2022)
Matthew Fabbro, Kirah Hahn, Olivia Novaes, Mícheál Ó'Grálaigh, James F O'Mahony
Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification. PharmacoEconomics - open 6 (6) (2022)
James F O'Mahony
Comment on Keeney et al.'s "Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening". PharmacoEconomics 39 (8) (2021)
James F O'Mahony
Revision of Ireland's Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs. PharmacoEconomics - open 5 (3) (2021)
Suaad Almajed, Nora Alotaibi, Sana Zulfiqar, Zahraa Dhuhaibawi, Niall O'Rourke, Richard Gaule, Caoimhe Byrne, Aaron M Barry, Dylan Keeley, James F O'Mahony
Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability. The European journal of health economics : HEPAC : health economics in prevention and care (2021)
James F O'Mahony, Mike Paulden, Christopher McCabe
NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests. PharmacoEconomics 39 (2) (2021)
Michelle Q T Kwok, Mistura A Kareem, Michael J Cash, Fiona Lafferty, Katy Tobin, James F O'Mahony
Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses. PharmacoEconomics 38 (8) (2021)
James F O'Mahony
Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening: Intervention Eligibility, Strategy Choice, and Optimality. Medical decision making : an international journal of the Society for Medical Decision Making (2021)
James F O'Mahony
Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al. HRB open research 3 (2020)
James F O'Mahony
Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al. HRB open research (2020)
James F O'Mahony
Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit? PharmacoEconomics 38 (8) (2020)
Ethna McFerran, James F O'Mahony, Edward Goodall, Mark Lawler
Unacceptable variation in screening colonoscopy. BMJ (Clinical research ed.) 367 (2019)

James F O'Mahony.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

James F O'Mahony